Katharina Glatz

Katharina Glatz

Auto-generated profile, based on publicly available information

Katharina Glatz

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland. 4

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Metabolic Engineering
Verified
Journal Article
Closed access
BHBoon Chin Heng
Boon Chin Heng
KHKarl Heinimann
Karl Heinimann
PMPeter Miny
Peter Miny
GIGiandomenica Iezzi
Giandomenica Iezzi
KGKatharina Glatz
Katharina Glatz
MFMartin Fussenegger
Martin Fussenegger

17 April 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DKDavid König
David König
MSMichael T. Sandholzer
Michael T. Sandholzer
SUSarp Uzun
Sarp Uzun
AZAndreas Zingg
Andreas Zingg
RRReto Ritschard
Reto Ritschard
HLHeinz Läubli
Heinz Läubli
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients with melanoma, although long-term responses seem restricted in patients who have complete remissions. Many patients develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. In this study, we describe a case of secondary resistance to TIL-ACT possibly due to intratumoral heterogeneity and selection of a resistant tumor cell clone by the transferred T cells. To the best our knowledge, this is the first case of clonal selection of a pre-existing nondominant tumor cell clone; this report demonstrates the mechanism involved in secondary resistance to TIL-ACT that can potentially change current clinical practice because it advocates for T-cell collection from multiple tumor sites and analysis of tumor heterogeneity before treatment with TIL-ACT.

15 July 2007 in Der Pathologe
Verified
Journal Article
Closed access
PDF file
KGK. Glatz
K. Glatz
Lukas BubendorfLukas Bubendorf
Lukas Bubendorf
DGD. Glatz
D. Glatz

2 July 2024
Verified
Other
Open access
PDF file
DKDavid König
David König
MSMichael T. Sandholzer
Michael T. Sandholzer
SUSarp Uzun
Sarp Uzun
AZAndreas Zingg
Andreas Zingg
RRReto Ritschard
Reto Ritschard
HLHeinz Läubli
Heinz Läubli
Supplementary Figure 2. Regressing soft tissue metastasis (Biopsy 3 weeks after TIL transfer). Vital tumor areas (SOX10) are densely infiltrated by CD8 positive tumor infiltrating lymphocytes as shown by immunohistochemistry.

2 July 2024
Verified
Other
Open access
PDF file
DKDavid König
David König
MSMichael T. Sandholzer
Michael T. Sandholzer
SUSarp Uzun
Sarp Uzun
AZAndreas Zingg
Andreas Zingg
RRReto Ritschard
Reto Ritschard
HLHeinz Läubli
Heinz Läubli
Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.

2 July 2024
Verified
Other
Open access
PDF file
DKDavid König
David König
MSMichael T. Sandholzer
Michael T. Sandholzer
SUSarp Uzun
Sarp Uzun
AZAndreas Zingg
Andreas Zingg
RRReto Ritschard
Reto Ritschard
HLHeinz Läubli
Heinz Läubli
Supplementary Figure 4. Progressing lung metastasis (Wedge resection 61 weeks after TIL transfer). The resected lung metastasis is Melan-A positive without any desmoplastic component.